News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amorfix Life Sciences Ltd. Receives Third Biogen Idec, Inc. (Massachusetts) (BIIB) Investment


11/17/2008 11:42:19 AM

TORONTO, Nov. 17 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that Biogen Idec (Nasdaq:BIIB - News) made their third investment in Amorfix with the purchase of 608,250 shares for gross proceeds to Amorfix of US$150,000. With this investment, Biogen Idec maintains its right to license Amorfix's superoxide dismutase-1 (SOD1) targeted therapies for use in ALS.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES